Development

Articles

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe. 

BD to Invest $1.2 Billion Over Four Years in Pre-Fillable Syringe Manufacturing Capacity 

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Excipients must be carefully chosen to ensure optimum protection for vaccines and live biotherapeutic products.

Factoring Stability in the Biologic Drug Mix

The new line has the ability to aseptically fill powder, liquid, suspension, and combination forms into vials in clinical or commercial batch sizes. 

Evonik Qualifies Filling Line for Parenteral Drug Products at its Alabama Facility 

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

The authors compare formulations containing citrate with other buffers in reducing subcutaneous injection-site pain and discuss a formulation and excipients selection strategy.

Approaches to Alleviating Subcutaneous Injection-Site Pain for Citrate Formulations

The right approach to biological safety cabinets, and collaboration between engineers and those who will operate the equipment, is crucial to preventing cell-culture contamination. 

Minimizing Contamination During BioPharm R&D

Editor of Pharmaceutical Technology Europe

Considering the potential interaction of a drug with the delivery device early on in in development is integral to achieving the best combination.

Avoiding Negative Drug–Device Interactions

The company will showcase the syriQ BioPure syringe in a 2.25-mL format for autoinjectors at Pharmapack in Paris, France from Feb. 5¬¬–6, 2020. 

Schott to Present New Syringe Format at Pharmapack 2020

The facility will produce parenteral products and delivery devices and is set to create 460 new jobs.

Eli Lilly to Invest $470 Million into New Pharma Manufacturing Facility

Generic pharmaceutical company, Hikma Pharmaceuticals, and biopharmaceutical company, Arecor, have entered into an exclusive agreement for the development and commercialization of a ready-to-use injectable medicine.


Formulation and Drug Delivery, Parenterals